Get started
Author

Lisa Cooper

Observed name: Lisa D Cooper
ORCID: 0000-0002-2403-8105
Observed ORCID: 0000-0002-2403-8105
OpenAlex ID: A5103098204
Changes in Companion Diagnostic Labelling: Implementation of FDA’s April 2020 Guidance for Industry for In Vitro CDx Labeling for Specific Oncology Therapeutic Groups
2022 · Lisa Cooper, Joyce Chen · Therapeutic Innovation & Regulatory Science · 8
PDF
COVID-19 pandemic response varies by clinical trial sponsor type
2021 · Lisa Cooper, Irene Lee, et al. · Journal of Clinical and Translational Science · 3
PDF
396 Quantitative Analysis of FDA Warning Letters Related to the Use of Social Media Sites in Product Misbranding for the Treatment, Prevention, or Diagnosis of COVID-19
2023 · Mahmoud Ajaj, Lisa Cooper · Journal of Clinical and Translational Science · 1
PDF
A 15 Year Review (2006-2020) of Patient-Reported Outcomes (PRO) in United States Oncology Product Labeling and Trends in Sponsor Size and Oncology Experience
2021 · Lisa D Cooper, Emily Wo, et al. · Research Square · 1
PDF
48842 Sponsor types of US interventional COVID-19 studies listed in ClinicalTrials.gov
2021 · Irene Lee, Lisa Cooper, et al. · Journal of Clinical and Translational Science · 1
PDF
The Relationship Between COVID-19 Research Response and Trial Sponsor Type
2023 · Lisa Cooper
Works count: 6
Citation count: 14
H-index: 2
I10-index:
Year
Topic
Type